Alpha 2.0
Login Register
» Articles » PMID: 30762437

Impact of Human Factors Testing on Medical Device Design: Validation of an Automated CGM Sensor Applicator

Overview
Journal J Diabetes Sci Technol
Specialty Endocrinology
Date 2019 Feb 15
PMID 30762437
Citations 4
Authors
Robert North
Christine Pospisil
Ryan J Clukey
Christopher G Parkin
Affiliations
Soon will be listed here.
Abstract

Improving user engagement with continuous glucose monitoring (CGM) is considered a major requirement for achieving optimal treatment efficacy. Human factors testing is needed to ensure that CGM product designs and requisite training simplify the user experience and enhance usability and patient safety. Dexcom, Inc, recently introduced a novel, "one-button" automatic sensor applicator (ASA) for use with the Dexcom G6 (rtCGM) system. The device was developed utilizing all phases of the human factors testing process. We recruited eight certified diabetes educators from independent health care institutions to conduct a comparative ease-of-use analysis to confirm the usability of the ASA. Participants judged the instructions and device to be easier to use than the previous sensor applicator.

Citing Articles

Usability and Teachability of Continuous Glucose Monitoring Devices in Older Adults and Diabetes Educators: Task Analysis and Ease-of-Use Survey.

Psavko S, Katz N, Mirchi T, Green C JMIR Hum Factors. 2022; 9(4):e42057.

PMID: 36347498 PMC: 9801269. DOI: 10.2196/42057.

Comparisons of Fifth-, Sixth-, and Seventh-Generation Continuous Glucose Monitoring Systems.

Welsh J, Psavko S, Zhang X, Gao P, Balo A J Diabetes Sci Technol. 2022; 18(1):143-147.

PMID: 35695305 PMC: 10899839. DOI: 10.1177/19322968221099879.

Input of Patients for New Diabetes Technology Products.

Heinemann L, Klonoff D J Diabetes Sci Technol. 2021; 15(5):983-985.

PMID: 34384263 PMC: 8442195. DOI: 10.1177/19322968211033611.

The Lifebox Surgical Headlight Project: engineering, testing, and field assessment in a resource-constrained setting.

Starr N, Panda N, Johansen E, Forrester J, Wayessa E, Rebollo D Br J Surg. 2020; 107(13):1751-1761.

PMID: 32592513 PMC: 7938832. DOI: 10.1002/bjs.11756.

References
1.
Polonsky W, Hessler D . What are the quality of life-related benefits and losses associated with real-time continuous glucose monitoring? A survey of current users. Diabetes Technol Ther. 2013; 15(4):295-301. DOI: 10.1089/dia.2012.0298. View
2.
Beck R, Riddlesworth T, Ruedy K, Kollman C, Ahmann A, Bergenstal R . Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5(9):700-708. DOI: 10.1016/S2213-8587(17)30217-6. View
3.
Polonsky W, Hessler D, Ruedy K, Beck R . The Impact of Continuous Glucose Monitoring on Markers of Quality of Life in Adults With Type 1 Diabetes: Further Findings From the DIAMOND Randomized Clinical Trial. Diabetes Care. 2017; 40(6):736-741. DOI: 10.2337/dc17-0133. View
4.
Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline J, Rayman G . Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Ther. 2016; 8(1):55-73. PMC: 5306122. DOI: 10.1007/s13300-016-0223-6. View
5.
Lind M, Polonsky W, Hirsch I, Heise T, Bolinder J, Dahlqvist S . Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017; 317(4):379-387. DOI: 10.1001/jama.2016.19976. View